81 -12 (86) 2025 - Sayidova M.H. - AGE FEATURES OF THE IMMUNE SYSTEM AND THEIR INFLUENCE ON THE RESULTS OF TREATMENT FOR JUVENILE IDIOPATHIC ARTHRITIS

AGE FEATURES OF THE IMMUNE SYSTEM AND THEIR INFLUENCE ON THE RESULTS OF TREATMENT FOR JUVENILE IDIOPATHIC ARTHRITIS

Sayidova M.H. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

JIA in children is characterized by pronounced age-related variability of the immune response, which directly affects the effectiveness of the ongoing therapy. The purpose of the study was to assess the influence of age-related immunological changes on the therapeutic response and clinical outcomes in children with JIA when using various treatment regimens. The study included 112 children with JIA, divided into three age groups and three therapy regimens: basic therapy (methotrexate + NSAIDs), escalatory therapy (methotrexate + GCS), and biological therapy with Tocilizumab. It has been established that in school-age children, the level of clinical activity decreases significantly slower, despite therapy, which is associated with the formation of pronounced Th17-mediated autoaggression. The use of Tocilizumab made it possible to significantly reduce the activity of inflammation in patients with a persistent autoimmune profile, especially in the adolescent group.

Keywords: JIA, therapeutic effectiveness, age characteristics, Tocilizumab, methotrexate, corticosteroids, immunoregulation, clinical outcomes.

First page

445

Last page

449

For citation:Sayidova M.H. - AGE FEATURES OF THE IMMUNE SYSTEM AND THEIR INFLUENCE ON THE RESULTS OF TREATMENT FOR JUVENILE IDIOPATHIC ARTHRITIS//New Day in Medicine 12(86)2025 445-449 https://newdayworldmedicine.com/en/new_day_medicine/12-86-2025

List of References

1. Соловев M.M. Ювенильные артриты у детей. – Москва: ГЭОТАР-Медиа, 2022. – 368 с.
2. Хальчицкий С.Е., Грачева Ю.А. Системный ювенильный идиопатический артрит и его Биомаркеры Medline.Ru, ПЕДИАТРИЯ, 2023 25 марта; том 24.
3. Petty R.E., Laxer R., Lindsley C., Wedderburn L. Textbook of Pediatric Rheumatology. – 8th edition. – Elsevier Publishing, Philadelphia, 2021. – 832 p.
4. Martini A., Ravelli A., Caporali R. Personalized treatment approaches in juvenile idiopathic arthritis // The Lancet Rheumatology. 2023;5(3):188-200.
5. Quartier P., Allantaz F., Cimaz R. Juvenile idiopathic arthritis: treatment stratification and modern biological therapy // Nature Reviews Rheumatology. 2021;17:456–472.
6. Hinze C., Foell D. Cytokines and therapeutic resistance in pediatric arthritis // Annals of the Rheumatic Diseases. 2023;82(5):912–926.
7. Ravelli A., Martini A. Clinical management standards and disease-modifying treatment recommendations in JIA // Rheumatology. 2022;61(4):1520–1531.
8. Beukelman T., et al. Comparative effectiveness of methotrexate-based regimens in children with JIA // Arthritis Rheumatology. 2023;75(9):1128–1141.
9. Nigrovic P.A., Sundel R. New therapeutic horizons in pediatric autoimmune arthritis // Nature Immunology. 2020;21(9):1064–1072.
10. Teplyakov A.A. Tocilizumab in pediatric practice: clinical implementation and safety monitoring // Pediatric Clinical Pharmacology Journal. 2023;30(2):45-54.
11. Тухтаев А.К., Каримов У., Хабибуллаев Ш.Ю. Эффективность биологической терапии у детей с ревматическими заболеваниями в Республике Узбекистан // Tashkent Medical Journal. 2024;3(42):55-64.

    file

    download